These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9304336)

  • 1. [A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine].
    Zakharova NS; Shmeleva EI; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Mertsalova NU; Britsina MV; Ermolova EV; Zaĭtsev EM
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):70-2. PubMed ID: 9304336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [An acellular pertussis vaccine based on the natural complex of antigens isolated from the supernatant of a synthetic culture medium].
    Zakharova NS; Remova TN; Bazhanova IG; Ozeretskovskaia MH; Britsina MV; Shmeleva EI; Mertsalova NU; Ermolova EI; Sukhinova EE; Bulk VF; Sirotinskiĭ AV; Poluiianova AG; Sviridov VV; Vartanian IuP
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (3):67-70. PubMed ID: 9304334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunobiologic activity of Bordetella pertussis strains defective in various virulence factors].
    Smirnov VD; Chuprinina RP; Siundiukova RA; Maksiutov RV
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Mar; (3):8-10. PubMed ID: 2545060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
    Boros CA; Hanlon M; Gold MS; Roberton DM
    Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
    Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
    Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The development of a new generation of pertussis vaccine].
    Chuprinina RP; Bychenko BD; Smirnov VD; Maksiutov RV; Eglit IuKh
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Oct; (10):89-94. PubMed ID: 2075771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
    Sato Y; Sato H
    Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
    Halperin SA; Barreto L; Friesen B; Meekison W
    Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for a new acellular pertussis vaccine.
    Manclark CR; Burns DL
    Ann Inst Pasteur Microbiol (1985); 1985; 136B(3):323-9. PubMed ID: 2870676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.